
Elicio Therapeutics prices $15M stock offering to fund cancer immunotherapy trials.
Elicio Therapeutics has priced a $15 million registered direct offering of common stock to support the Phase 1 clinical development of its lead immunotherapy candidate, ELI-002 7P, targeting KRAS-driven metastatic pancreatic cancer. The offering invo...



